دانلود کتاب هندبوک درمانی آنتی بادی (۴ جلدی)
Handbook of Therapeutic Antibodies, 2ed

Still the most comprehensive reference source on the development, production and therapeutic application of antibodies, this second edition is thoroughly updated and now has 30% more content.

Volume 1 covers selection and engineering strategies for new antibodies, while the second volume presents novel therapeutic concepts and antibodies in clinical study, as well as their potential. Volumes 3 and 4 feature detailed and specific information about each antibody approved for therapeutic purposes, including clinical data. This unique handbook concludes with a compendium of marketed monoclonal antibodies and an extensive index.

Beyond providing current knowledge, the authors discuss emerging technologies, future developments, and intellectual property issues, such that this handbook meets the needs of academic researchers, decision makers in industry and healthcare professionals in the clinic.

About the Author

Stefan Dübel received his Ph.D. at the Center for Molecular Biology in Heidelberg, Germany, before moving on to the German Cancer Research Center in 1989 where he started research on the development of antibody libraries with naive or synthetic CDRs. In the following years, he substantially participated in the invention of antibody phage display, as well as other recombinant antibody technologies and the development of various antibody fusion proteins. In 1996, he moved to the University of Heidelberg to establish the antibody engineering group at the Institute of Molecular Genetics. He was appointed full professor at the Technische Universität Braunschweig in 2002, where he currently is head of the Department of Biotechnology and managing director of the Institute of Biochemistry, Biotechnology and Bioinformatics. He has co-authored more than 100 original papers, many patents, as well as several acknowledged textbooks in the field of recombinant antibodies. He is also on the editorial board of several scientific journals and cofounder of two antibody engineering companies.

Janice M. Reichert is an internationally recognized expert in the development of antibody therapeutics. She is Founder and Managing Director of Reichert Biotechnology Consulting LLC, a pharmaceutical business intelligence research firm, and the founding Editor-in-Chief of “mAbs”, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development. Dr. Reichert has published extensively on development trends for antibody therapeutics and she has presented her research results as an invited speaker at conferences held worldwide. She is President of The Antibody Society and serves on the editorial boards of several biomedical journals. Dr. Reichert received her Ph.D. from the University of Pennsylvania and her post-doctoral training at Harvard Medical School.

Contents

Volume I: Defining the Right Antibody Composition

Chapter 1 Therapeutic Antibodies – from Past to Future
Part I: Selecting and Shaping the Antibody Molecule
Part II: Modified Antibodies
Part III: Emerging Technologies

Volume II: Clinical Development of Antibodies

Part IV: The Way into the Clinic
Part V: Therapeutic Antibody Pipeline
Part VI: Gaining Marketing Approval

Volume III: Approved Therapeutic Antibodies

Part VII: Approved Therapeutic Antibodies

Volume IV: Approved Therapeutic Antibodies and in vivo Diagnostics

Chapter 63 Ofatumumab [Arzerra®}: a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxici
Chapter 64 Omalizumab [Xolair} – Anti-Immunoglobulin E Treatment in Allergic Diseases
Chapter 65 Palivizumab [Synagis®}
Chapter 66 Panitumumab [Vectibix®}: A Treatment for Metastatic Colorectal Cancer
Chapter 67 Pertuzumab (Peijeta®]
Chapter 68 Ranibizumab [Lucentis}: a New Anti-Angiogenic Treatment in Ophthalmology
Chapter 69 Raxibacumab, Human Monoclonal Antibody against Anthrax Toxin
Chapter 70 Rituximab [Rituxan®}
Chapter 71 Tocilizumab [Actemra®)
Chapter 72 Trastuzumab (Herceptin®} and Ado-Trastuzumab Emtansine [Kadcyla®}: Treatments for HER2-Positive Breast Cancer
Chapter 73 Ustekinumab [Stelara®l)
Chapter 74 Abciximab [Reopro®], Bevacizumab [Avastin®}, Certolizumab Pegol [Cimzia®], Eculizumab (Soliris®), Natalizumab (Tysabr®}
Chapter 75 Itolizumab [Alzumab®], Mogamulizumab [Poteligeo®), and Tositumomab [Bexxar®]
Part VIII: In vivo Diagnostics